Immunotherapy Strategies in Multiple Myeloma

Hematology/Oncology Clinics of North America

Volumn 28, Issue 5, 2014, Pages 927-943

  Bae, Jooeun ^a   Munshi, Nikhil C ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Active specific immunotherapy; Multiple myeloma; Passive specific immunotherapy

Indexed keywords

B CELL MATURATION ANTIGEN MONOCLONAL ANTIBODY; BIOLOGICAL MARKER; CANCER TESTIS ANTIGEN; CANCER VACCINE; CELL SURFACE PROTEIN; DARATUMUMAB; DENDRITIC CELL VACCINE; DEXAMETHASONE; DICKKOPF 1 PROTEIN; ELOTUZUMAB; LENALIDOMIDE; LORVOTUZUMAB MERTANSINE; MONOCLONAL ANTIBODY; PEPTIDE VACCINE; SYNDECAN 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; FUNCTIONAL DISEASE; HUMAN; MULTIPLE MYELOMA; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR MICROENVIRONMENT; AUTOTRANSPLANTATION; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PROCEDURES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TRENDS;

ANTIGENS, NEOPLASM; CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84912075259     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.07.002     Document Type: Review

References (135)

1. Kumar S.K., Dispenzieri A., Lacy M.Q., et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014, 28:1122-1128.
2. Laubach J.P., Richardson P.G., Anderson K.C. The evolution and impact of therapy in multiple myeloma. Med Oncol 2010, 27(Suppl 1):S1-S6.
3. Yi Q. Novel immunotherapies. Cancer J 2009, 15:502-510.
4. Barlogie B., Jagannath S., Desikan K.R., et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999, 93:55-65.
5. Rapoport A.P., Aqui N.A., Stadtmauer E.A., et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res 2014, 20:1355-1365.
6. Garcia-Marquez M.A., Shimabukuro-Vornhagen A., Theurich S., et al. Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?. Immunotherapy 2013, 5:1039-1042.
7. Bae J., Smith R., Daley J., et al. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res 2012, 18:4850-4860.
8. Ocio E.M., Richardson P.G., Rajkumar S.V., et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014, 28:525-542.
9. van de Donk N.W., Kamps S., Mutis T., et al. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia 2012, 26:199-213.
10. Richardson P.G., Lonial S., Jakubowiak A.J., et al. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 2011, 154:745-754.
11. Rossi M., Botta C., Correale P., et al. Immunologic microenvironment and personalized treatment in multiple myeloma. Expert Opin Biol Ther 2013, 13(Suppl 1):S83-S93.
12. Tai Y.T., Dillon M., Song W., et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008, 112:1329-1337.
13. Zonder J.A., Mohrbacher A.F., Singhal S., et al. Aphase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012, 120:552-559.
14. Lonial S., Vij R., Harousseau J.L., et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. JClin Oncol 2012, 30:1953-1959.
15. Richardson P.G., Jagannath S., Moreau P., et al. Aphase 2 study of elotuzumab (Elo) in combination with lenalidomide and low-dose dexamethasone (Ld) in patients (pts) with relapsed/refractory multiple myeloma (R/R MM): updated results. ASH Ann Meet Abstr 2012, 120:202.
16. Plesner T., Lokhorst H., Gimsing P., et al. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma-data from a dose-escalation phase I/II study. ASH Ann Meet Abstr 2012, 120:73.
17. Lokhorst H.M., Plesner T., Gimsing P., et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. ASCO Meet Abstr 2013, 31(15 Suppl):8512.
18. Heffner L.T., Jagannath S., Zimmerman T.M., et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: safety and further evidence of clinical activity. ASH Ann Meet Abstr 2012, 120:4042.
19. Jagannath S., Chanan-Khan A., Heffner L.T., et al. BT062, an antibody-drug conjugate directed against CD138, Shows clinical activity in patients with relapsed or relapsed/refractory multiple myeloma. ASH Ann Meet Abstr 2011, 118:305.
20. Bensinger W., Maziarz R.T., Jagannath S., et al. Aphase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol 2012, 159:58-66.
21. Hussein M., Berenson J.R., Niesvizky R., et al. Aphase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010, 95:845-848.
22. Rosenblatt J., Glotzbecker B., Mills H., et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances exvivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. JImmunother 2011, 34:409-418.
23. Benson D.M., Bakan C.E., Mishra A., et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010, 116:2286-2294.
24. White D., Kassim A., Bhaskar B., et al. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer 2013, 119:339-347.
25. Voorhees P.M., Manges R.F., Sonneveld P., et al. Aphase 2 multicenter study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. ASH Ann Meet Abstr 2011, 118:3971.
26. Rossi J.F., Manges R.F., Sutherland H.J., et al. Preliminary results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. ASH Ann Meet Abstr 2008, 112:867.
27. Benson D.M., Hofmeister C.C., Padmanabhan S., et al. Aphase I trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012, 120:4324-4333.
28. Slezak S.L., Worschech A., Wang E., et al. Analysis of vaccine-induced T cells in humans with cancer. Adv Exp Med Biol 2010, 684:178-188.
29. Westers T.M., van den Ancker W., Bontkes H.J., et al. Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells. Immunotherapy 2011, 3:569-576.
30. Tricot G., Jagannath S., Vesole D.H., et al. Hematopoietic stem cell transplants for multiple myeloma. Leuk Lymphoma 1996, 22:25-36.
31. Verdonck L.F., Lokhorst H.M., Dekker A.W., et al. Graft-versus-myeloma effect in two cases. Lancet 1996, 347:800-801.
32. King C.A., Spellerberg M.B., Zhu D., et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998, 4:1281-1286. [see comment].
33. Campbell M.J., Esserman L., Byars N.E., et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. JImmunol 1990, 145:1029-1036.
34. Szea D.M., Brown R.D., Yang S., et al. Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leuk Lymphoma 2003, 44:1557-1568.
35. Hansson L., Rabbani H., Fagerberg J., et al. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood 2003, 101:4930-4936.
36. Romagnani S. Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 1992, 98:279-285.
37. Yi Q., Osterborg A., Bergenbrant S., et al. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995, 86:3043-3049.
38. Röllig C., Schmidt C., Bornhäuser M., et al. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. JImmunother 2011, 34(1):100-106.
39. Yi Q., Szmania S., Freeman J., et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol 2010, 150(5):554-564.
40. Rasmussen T., Hansson L., Osterborg A., et al. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003, 101:4607-4610.
41. Massaia M., Borrione P., Battaglio S., et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999, 94:673-683.
42. Titzer S., Christensen O., Manzke O., et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000, 108:805-816.
43. Romano E., Rossi M., Ratzinger G., et al. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation invitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells invivo. Clin Cancer Res 2011, 17:1984-1997.
44. Lacy M.Q., Mandrekar S., Dispenzieri A., et al. Idiotype pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol 2009, 84(12):799-802.
45. Gong J., Koido S., Chen D., et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 2002, 99:2512-2517.
46. Vasir B., Borges V., Wu Z., et al. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol 2005, 129(5):687-700.
47. Luptakova K., Rosenblatt J., Glotzbecker B., et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 2013, 62:39-49.
48. Rosenblatt J., Avivi I., Vasir B., et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013, 19:3640-3648.
49. Yang D.H., Kim M.H., Hong C.Y., et al. Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Ann Hematol 2010, 89(8):795-801.
50. Lee J.J., Choi B.H., Kang H.K., et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk Lymphoma 2007, 48(10):2022-2031.
51. Wen Y.J., Min R., Tricot G., et al. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 2002, 99(9):3280-3285.
52. Milazzo C., Reichardt V.L., Müller M.R., et al. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003, 101(3):977-982.
53. Hayashi T., Hideshima T., Akiyama M., et al. Exvivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003, 102(4):1435-1442.
54. Qian J., Hong S., Wang S., et al. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood 2009, 114(18):3880-3889.
55. Qian J., Wang S., Yang J., et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTL using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res 2005, 11(24):8808-8815.
56. Dudek N.L., Perlmutter P., Aguilar M.I., et al. Epitope discovery and their use in peptide based vaccines. Curr Pharm Des 2010, 16:3149-3157.
57. Disis M.L., Bernhard H., Jaffee E.M. Use of tumour-responsive T cells as cancer treatment. Lancet 2009, 373:673-683.
58. Parvanova I., Rettig L., Knuth A., et al. The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. Vaccine 2011, 29:3832-3836.
59. Jagannath S., Kyle R.A., Palumbo A., et al. The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma Leuk 2010, 10:28-43.
60. Bensinger W.I. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 2009, 23:442-448.
61. Zeiser R., Finke J. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect. Eur J Cancer 2006, 42:1601-1611.
62. Abdalla A.O., Kokhaei P., Hansson L., et al. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC). Ann Oncol 2008, 19:1172-1179.
63. Lee K., Tirasophon W., Shen X., et al. IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev 2002, 16:452-466.
64. Mori K. Frame switch splicing and regulated intramembrane proteolysis: key words to understand the unfolded protein response. Traffic 2003, 4:519-528.
65. Bagratuni T., Wu P., Gonzalez de Castro D., et al. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood 2010, 116:250-253.
66. Patterson J., Palombella V.J., Fritz C., et al. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol 2008, 61:923-932.
67. Bae J., Carrasco R., Lee A.H., et al. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia 2011, 25(10):1610-1619.
68. Bharti A.C., Shishodia S., Reuben J.M., et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004, 103:3175-3184.
69. Wolowiec D., Dybko J., Wrobel T., et al. Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm 2006, 2006:42394-42399.
70. Sanderson R.D., Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 2008, 25:149-159.
71. Yang Y., Yaccoby S., Liu W., et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002, 100:610-617.
72. Bae J., Tai Y.T., Anderson K.C., et al. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol 2011, 155(3):349-361.
73. van Rhee F., Szmania S.M., Dillon M., et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 2009, 8:2616-2624.
74. Hsi E.D., Steinle R., Balasa B., et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008, 14:2775-2784.
75. Zhan F., Sawyer J., Tricot G. The role of cytogenetics in myeloma. Leukemia 2006, 20:1484-1486.
76. Bae J., Song W., Smith R., et al. Anovel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol 2012, 157:687-701.
77. Bae J., Voskertchian A., Prabhala R., et al. Amultiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia 2014, 10.1038/leu.2014.159.
78. Zorn A.M. Wnt signalling: antagonistic Dickkopfs. Curr Biol 2001, 11:R592-R595.
79. Mao B., Wu W., Li Y., et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001, 411:321-325.
80. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. NEngl J Med 2003, 349:2483-2494.
81. Krupnik V.E., Sharp J.D., Jiang C., et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999, 238:301-313.
82. Kohn M.J., Kaneko K.J., DePamphilis M.L. DkkL1 (Soggy), a Dickkopf family member, localizes to the acrosome during mammalian spermatogenesis. Mol Reprod Dev 2005, 71:516-522.
83. Hall C.L., Bafico A., Dai J., et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005, 65:7554-7560.
84. Qian J., Xie J., Hong S., et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 2007, 110:1587-1594.
85. Giannopoulos K., Własiuk P., Dmoszyńska A., et al. Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia. Folia Histochem Cytobiol 2001, 49:161-167.
86. Giannopoulos K., Mertens D., Bühler A., et al. The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia 2009, 23:519-527.
87. Greiner J., Schmitt M., Li L., et al. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 2006, 108:4109-4117.
88. Schmitt M., Schmitt A., Rojewski M.T., et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008, 111:1357-1365.
89. Greiner J., Schmitt A., Giannopoulos K., et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 2010, 95:1191-1197.
90. Pellat-Deceunynck C., Mellerin M.P., Labarriere N., et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol 2000, 30:803-809.
91. Gupta S.K., Shaughnessy J., Droojenbroeck J.V., et al. NY-ESO-1 RNA and protein expression in multiple myeloma is highest in aggressive myeloma and is correlated with chromosomal abnormalities. Blood 2002, 100:401a.
92. Simpson A.J., Caballero O.L., Jungbluth A., et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005, 5:615-625.
93. Szmania S.M., Bennett G., Batchu R.B., et al. Dendritic cells pulsed with NY-ESO-1 and MAGE-3 peptide stimulate myeloma cytotoxic T lymphocytes. Blood 2002, 100:399a.
94. van Rhee F., Szmania S.M., Zhan F., et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005, 105:3939-3944.
95. Akagi J., Nakagawa K., Egami H., et al. Induction of HLA-unrestricted and HLA-class-II restricted cytotoxic T lymphocytes against MUC-1 from patients with colorectal carcinomas using recombinant MUC-1 vaccinia virus. Cancer Immunol Immunother 1998, 47:21-31.
96. Moore A., Medarova Z., Potthast A., et al. Invivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004, 64:1821-1827.
97. Lim S.H., Wang Z., Chiriva-Internati M., et al. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001, 97:1508-1510.
98. Lim S.H., Chiriva-Internati M., Wang Z., et al. Sperm protein 17 (Sp17) as a tumor vaccine for multiple myeloma. Blood 2002, 100:673a.
99. Treon S.P., Raje N., Anderson K.C. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol 2000, 27:598-613.
100. Ohtomo T., Sugamata Y., Ozaki Y., et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 1999, 258:583-591.
101. Anderson L.D., Cook D.R., Yamamoto T.N., et al. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother 2011, 60:985-997.
102. Descamps G., Gomez-Bougie P., Venot C., et al. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 2009, 100(2):366-369.
103. Lacy M.Q., Alsina M., Fonseca R., et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008, 26(19):3196-3203.
104. Carlo-Stella C., Guidetti A., Di Nicola M., et al. IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3. Cancer Res 2007, 67(7):3269-3275.
105. Yu C., Liu Q., Gao W., et al. Monoclonal antibodies directed against chicken β2-microglobulin developed with a synthesized peptide. Monoclon Antib Immunodiagn Immunother 2013, 32(3):205-210.
106. Cao Y., Lan Y., Qian J., et al. Targeting cell surface b2-microglobulin by pentameric IgM antibodies. Br J Haematol 2011, 154(1):111-121.
107. Tai Y.T., Mayes P.A., Acharya C., et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 2014, 123(20):3128-3138.
108. Ryan M.C., Hering M., Peckham D., et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther 2007, 6(11):3009-3018.
109. Lyu M.A., Cheung L.H., Hittelman W.N., et al. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 2007, 6(2):460-470.
110. Sekimoto E., Ozaki S., Ohshima T., et al. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res 2007, 67(3):1184-1192.
111. Rossi E.A., Rossi D.L., Stein R., et al. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res 2010, 70(19):7600-7609.
112. Amano J., Masuyama N., Hirota Y., et al. Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody. Drug Metab Dispos 2010, 38(12):2339-2346.
113. Ozaki S., Kosaka M., Wakahara Y., et al. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood 1999, 93(11):3922-3930.
114. Deckert J., Wetzel M.C., Bartle L.M., et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent anti-tumor activity in models ofmultiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res 2014, pii:clincanres.0695.2014.
115. McEarchern J.A., Smith L.M., McDonagh C.F., et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 2008, 14(23):7763-7772.
116. Chérel M., Gouard S., Gaschet J., et al. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med 2013, 54(9):1597-1604.
117. Tassone P., Goldmacher V.S., Neri P., et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004, 104(12):3688-3696.
118. Kamath A.V., Lu D., Gupta P., et al. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma. Cancer Chemother Pharmacol 2012, 69(4):1071-1078.
119. Trudel S., Stewart A.K., Rom E., et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006, 107(10):4039-4046.
120. Sainz I.M., Isordia-Salas I., Espinola R.G., et al. Multiple myeloma in a murine syngeneic model:modulation of growth and angiogenesis by a monoclonal antibody to kininogen. Cancer Immunol Immunother 2006, 55(7):797-807.
121. Veitonmäki N., Hansson M., Zhan F., et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell 2013, 23(4):502-515.
122. Smallshaw J.E., Coleman E., Spiridon C., et al. The generation and anti-myeloma activity of a chimeric anti-CD54 antibody, cUV3. J Immunother 2004, 27(6):419-424.
123. Coleman E.J., Brooks K.J., Smallshaw J.E., et al. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines. J Immunother 2006, 29(5):489-498.
124. Fulciniti M., Hideshima T., Vermot-Desroches C., et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009, 15(23):7144-7152.
125. Yoshio-Hoshino N., Adachi Y., Aoki C., et al. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res 2007, 67(3):871-875.
126. Yaccoby S., Pennisi A., Li X., et al. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 2008, 22(2):406-413.
127. Menoret E., Gomez-Bougie P., Geffroy-Luseau A., et al. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 2006, 108(4):1346-1352.
128. Lacy M.Q., Mandrekar S., Dispenzieri A., et al. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol 2009, 84(12):799-802.
129. Liso A., Stockerl-Goldstein K.E., Auffermann-Gretzinger S., et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000, 6(6):621-627.
130. Titzer S., Christensen O., Manzke O., et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000, 108(4):805-816.
131. Reichardt V.L., Milazzo C., Brugger W., et al. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica 2003, 88(10):1139-1149.
132. Abdalla A.O., Hansson L., Eriksson I., et al. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients. Eur J Haematol 2007, 79(5):371-381.
133. Rosenblatt J., Avivi I., Vasir B., et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013, 19(13):3640-3648.
134. Tsuboi A., Oka Y., Nakajima H., et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol 2007, 86(5):414-417.
135. Greiner J., Schmitt A., Giannopoulos K., et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 2010, 95(7):1191-1197.